Scarica l'app Stockscreener
14.93
2.10%
-0.32
Dopo l'orario di chiusura:
14.93
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$15.25
Aprire:
$15.16
Volume 24 ore:
22.03M
Relative Volume:
2.41
Capitalizzazione di mercato:
$17.20B
Reddito:
$14.33B
Utile/perdita netta:
$-3.79B
Rapporto P/E:
-4.7098
EPS:
-3.17
Flusso di cassa netto:
$1.84B
1 W Prestazione:
-6.22%
1M Prestazione:
+13.80%
6M Prestazione:
+43.28%
1 anno Prestazione:
+56.66%
Intervallo 1D:
$14.85
$15.50
Intervallo di 1 settimana:
$14.85
$16.47
Portata 52W:
$6.85
$16.47
Viatris Inc Stock (VTRS) Company Profile
Nome
Viatris Inc
Settore
Telefono
(724) 514-1465
Indirizzo
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
14.93 | 17.56B | 14.33B | -3.79B | 1.84B | -3.17 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.75 | 58.54B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
131.10 | 54.78B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
11.07 | 47.92B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.86 | 39.33B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
503.90 | 21.68B | 3.13B | 1.27B | 1.12B | 26.39 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-09 | Aggiornamento | UBS | Neutral → Buy |
| 2026-01-16 | Aggiornamento | Argus | Hold → Buy |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-10-15 | Iniziato | Truist | Buy |
| 2025-06-06 | Iniziato | Goldman | Neutral |
| 2024-07-19 | Ripresa | Jefferies | Buy |
| 2023-10-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-10 | Aggiornamento | UBS | Sell → Neutral |
| 2022-11-08 | Aggiornamento | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Ripresa | Jefferies | Hold |
| 2022-06-14 | Iniziato | UBS | Sell |
| 2022-05-10 | Downgrade | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Iniziato | Citigroup | Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-03-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Iniziato | Argus | Hold |
| 2020-12-14 | Iniziato | Bernstein | Mkt Perform |
Mostra tutto
Viatris Inc Borsa (VTRS) Ultime notizie
UBS raises Viatris stock price target to $20 on cost savings - Investing.com India
UBS Adjusts Viatris Price Target to $20 From $18, Maintains Buy Rating - marketscreener.com
Rx Rundown: Gilead Sciences, Viatris, Generate Biomedicines and more - Medical Marketing and Media
Viatris Inc. (NASDAQ:VTRS) Q4 2025 Earnings Call Transcript - Insider Monkey
Viatris Inc. (VTRS) FDA Accepts sNDA for Presbyopia Treatment with October PDUFA Date - Yahoo Finance UK
JPMorgan Adjusts Price Target on Viatris to $17 From $16, Maintains Neutral Rating - marketscreener.com
Decoding Viatris Inc (VTRS): A Strategic SWOT Insight - GuruFocus
BofA raises Viatris stock price target on cost-cutting plan - Investing.com UK
Is Strong Q4 Revenue And Steady Dividend Policy Altering The Investment Case For Viatris (VTRS)? - simplywall.st
Viatris Looks Well-Positioned for Durable Growth From New Launches and Cost Savings Initiatives - Morningstar
Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up - Yahoo Finance
Viatris Q4 2025 slides: earnings beat, major cost-cutting plan By Investing.com - Investing.com South Africa
Restructuring: Viatris to cut global workforce by about 10% - Pittsburgh Post-Gazette
The Pivot to Growth: Viatris (VTRS) Enters Phase 2 with 2026 Dividend and Capital Allocation Strategy - FinancialContent
Viatris (VTRS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Viatris (VTRS) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance
Viatris forecasts 2026 profit below estimates on India manufacturing woes - marketscreener.com
Viatris Launches Major Restructuring After Strong 2025 Results - TipRanks
Viatris maintains annual dividend at 48 cents for 2026 - Investing.com
Viatris shares fall on lower-than-expected 2026 profit outlook - Investing.com Australia
Viatris Posts Narrower Loss In Q4; Expects Workforce Reduction Of Up To Approx. 10% - Nasdaq
Viatris beats on Q4; eyes 10% staff reduction (VTRS:NASDAQ) - Seeking Alpha
Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q4 CY2025 - TradingView
Viatris: Q4 Earnings Snapshot - marketscreener.com
Viatris beats estimates, stock edges up By Investing.com - Investing.com UK
Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results - PR Newswire
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend - PR Newswire
Viatris Inc. Stock Nears 52-Week High Ahead of Q4 Earnings: Shares Climb on Pipeline Strength - International Business Times Australia
Key facts: FDA Accepts Viatris' MR-141 Application; Q4 Results Due Soon - TradingView
Investors await Viatris earnings amid cost-cutting optimism By Investing.com - Investing.com
Viatris Q4 2025 Earnings Preview: Revenue Forecast & Analyst ExpectationsNews and Statistics - IndexBox
Analysts optimistic ahead of Viatris' Q4 earnings driven by healthy drugs pipeline - Seeking Alpha
FDA accepts Viatris presbyopia treatment application - Investing.com
Viatris, Opus gain as FDA to review label expansion for eyecare drug - Seeking Alpha
FDA Accepts Viatris Inc. Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia - marketscreener.com
FDA accepts Viatris supplemental new drug application for Mr-141 (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia - marketscreener.com
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia - The AI Journal
FDA Accepts Viatris Supplemental New Drug Application For Mr-141 (Phentolamine Ophthalmic Solution 0.75%) For The Treatment Of Presbyopia - TradingView
Earnings To Watch: Viatris (VTRS) Reports Q4 Results Tomorrow - Yahoo Finance UK
Viatris stock hits 52-week high at $16.31 - Investing.com
Viatris (BIT:1VTRS) Price Target Increased by 12.32% to 11.92 - Nasdaq
Will UBS Upgrade And Inpefa’s First Global Launch Change Viatris' (VTRS) Narrative? - Yahoo Finance
Unveiling Viatris (VTRS) Q4 Outlook: Wall Street Estimates for Key Metrics - Yahoo Finance
What's in Store for These 5 Medical Companies This Earnings Season? - TradingView
Viatris Stock to Report Q4 Earnings: What's in the Cards? - TradingView
Viatris Inc. (VTRS) Investor Outlook: Navigating a 3.02% Dividend Yield Amidst Healthcare Opportunities - DirectorsTalk Interviews
UBS Cite Efficient Capital Allocation and Rising Profits in Viatris Inc. (VTRS) Upgrade - MSN
Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation - Seeking Alpha
Shareholders of Viatris Inc. Should Contact Levi & Korsinsky Bef - GuruFocus
Earnings Preview: Viatris (VTRS) Q4 Earnings Expected to Decline - Finviz
Where is Viatris Inc. (VTRS) headed according to the Street? - MSN
Viatris Inc Azioni (VTRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.23%
0.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):